Equities

Perspective Therapeutics Inc

Perspective Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)13.47
  • Today's Change0.12 / 0.90%
  • Shares traded780.35k
  • 1 Year change+371.64%
  • Beta1.4735
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy2
Outperform5
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 6 analysts offering 12 month price targets for Perspective Therapeutics Inc have a median target of 23.00, with a high estimate of 27.00 and a low estimate of 17.00. The median estimate represents a 70.75% increase from the last price of 13.47.
High100.4%27.00
Med70.7%23.00
Low26.2%17.00

Earnings history & estimates in USD

On Aug 12, 2024, Perspective Therapeutics Inc reported 2nd quarter 2024 losses of -0.18 per share. This result exceeded the -0.21 consensus loss of the 5 analysts covering the company and exceeded last year's 2nd quarter results by 10.00%.
The next earnings announcement is expected on Nov 14, 2024.
Average growth rate-2.50%
Perspective Therapeutics Inc reported annual 2023 losses of -1.70 per share on Mar 31, 2024.
Average growth rate+41.86%
More ▼

Revenue history & estimates in USD

IsoRay, Inc. had 2nd quarter 2024 revenues of 526.00k. This bettered the 159.00k consensus of the 6 analysts covering the company. This was 69.37% below the prior year's 2nd quarter results.
Average growth rate-27.75%
IsoRay, Inc. had revenues for the full year 2023 of 8.37m. This was 22.46% below the prior year's results.
Average growth rate-27.30%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.